Navigation Links
Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
Date:5/8/2008

ATLANTA, May 8 /PRNewswire/ -- Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company announced today that enrollment has begun for a pilot study to assess the safety and efficacy of Medidur FA in conjunction with Lucentis(R) (ranibizumab injection, Genentech) in patients with exudative age-related macular degeneration (wet AMD).

This pilot study, which will be performed under an investigator sponsored IND, will compare two doses of Medidur FA (0.2 and 0.5 ug/day) in patients who have been treated with Lucentis for at least six months. The change from baseline in parameters such as visual acuity and retinal thickness will be assessed, in addition to comparing the number of Lucentis injections post- randomization versus pre-randomization. It has been previously shown that Lucentis requires persistent dosing to maintain efficacy.

"Alimera Sciences is pleased to support this study design because it will provide preliminary information on the potential of Medidur FA to maintain the efficacy established with Lucentis while reducing the number of Lucentis treatments," said Dr. Ken Green, Senior VP and Chief Scientific Officer for Alimera Sciences.

Lucentis is an antibody that binds to VEGF, thus preventing it from interacting with its receptor and causing additional damage in patients with wet AMD. Corticosteroids inhibit VEGF secretion in addition to their anti- inflammatory action and ability to suppress leukostasis. Given these complementary actions, the concomitant use of Lucentis and Medidur is warranted in patients being treated with Lucentis for wet AMD.

AMD is a degenerative disease of the central portion of the retina (the macula) which typically occurs in patients over the age of 50. One form of the disease, exudative (or wet) AMD is characterized by the formation of leaky new blood vessels originating in the choroid which may hemorrhage and cause accumulation of sub- and intra-retinal fluid. This form of AMD accounts for the majority of cases of severe vision loss. Medidur FA, a tiny, injectable intravitreal insert, is currently being studied as a way to deliver a very low dose of fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a treatment for diabetic macular edema (DME) in the FAME Phase III clinical trial. Using a proprietary 25 gauge injector system, an eye care professional injects the Medidur insert into the vitreous through a minimally invasive procedure in an outpatient setting.

About Alimera Sciences Inc.

Alimera Sciences Inc. is singularly focused on the development and commercialization of prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences' products are focused on improving the delivery of therapeutic agents to enhance patients' lives and strengthen physicians' ability to manage ocular conditions.

Alimera completed enrollment in October 2007 of its 956-patient Phase III clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the treatment of diabetic macular edema. Alimera has also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment for ophthalmic diseases. The agreement gives Alimera the exclusive option to license compounds which are NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidase inhibitors as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera retains the right to use the Medidur delivery system for two of these compounds.


'/>"/>
SOURCE Alimera Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pilot study reinforces use of portable anteroom HEPA filtration
2. Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO
3. Lake Hospital System Selected as Pilot Site for Health Information Literacy Research Project
4. NovoCure presents results from breast cancer pilot study
5. Researchers pilot new electronic system for infectious illness
6. VA to Pilot Innovative Remote Benefits Delivery Program
7. Phyhealth Concludes $1.5 Million Financing for Launch of Its Pilot Community-Based HMO
8. GHI and HIP Launch Pilot Medical Home Network Project with Support from Commonwealth Fund
9. Rockefeller Universitys Center for Clinical and Translational Science funds pilot studies
10. Pilot error declines as factor in airline mishaps
11. GDAHC Save Lives Save Dollars Initiative Launches Pilot Program for Diabetes Care Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... rates are on the rise, say researchers presenting their work at the ... Canada. , “The combination of evaluating the patterns of change in concussion symptom ...
(Date:7/20/2017)... Richmond, Va. (PRWEB) , ... July 20, 2017 , ... ... Daniel McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief ... of Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... and application performance monitoring (APM) solutions, has expanded its footprint inside the ... According to Peter Ohrenberger, sales director at Nastel, “We’ve replaced an existing ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... For individuals ... utmost importance. The adjustable beds used in such facilities are specially designed to accommodate ... adequate arm support. , An inventor from Rochester, Ind., has invented the patent-pending ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/13/2017)... 2017 RK Logistics Group, Inc. was awarded ... its Fremont, CA headquarters facility where ... and San Jose for hi-tech, pharmaceutical ... , with its Fremont Innovation District, is excited to ... powerful resource to the hundreds of biotech, pharma and biomed ...
(Date:7/12/2017)... -- CarpalAID is a revolutionary new product that relieves painful carpal ... tunnel syndrome affects more than 8 million people a year. Women ... The common methods of treating CTS are painful surgery, the use ... gloves. ... CarpalAID is a clear patch worn on the palm of the ...
Breaking Medicine Technology: